Company
Cordlife Group Limited
SGX:P8A
Cordlife collects, processes and cryogenically stores umbilical cord blood and cord tissue for private clients across several Asian markets, operating storage facilities rather than developing therapies. Its longevity relevance is as infrastructure for cell-based and regenerative medicine: banked haematopoietic stem cells are held against future transplant or therapeutic use. It is a storage and services business, not a therapeutics developer, and it does not run clinical programmes in ageing biology. Inclusion is on the listing limb (SGX Mainboard) and the Singapore headquarters, both confirmed. Fundamentals should be treated as unconfirmed: the company is under active Singapore Ministry of Health regulatory restriction and its FY2025 accounts carry a disclaimer of opinion.
At a glance
- Listing
- SGX:P8A
- Category
- Regenerative medicine
- Headquarters
- Singapore
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- Regenerative medicine
- Market
- Singapore
- Recent inflection
- On 23 April 2026, ahead of its 27 April 2026 AGM, Cordlife disclosed that its independent auditors had issued a disclaimer of opinion on the financial statements for the year ended 31 December 2025, citing unresolved regulatory and legal matters and an inability to verify opening balances as at 1 January 2025. This followed the Ministry of Health's one-year suspension of its licence to collect, test, process or store new cord blood units, effective 26 November 2025, and an MOH directive to replace the Chief Governance Officer and review laboratory records for roughly 160 cord blood units collected since January 2025. Source: Minichart AGM report, 23 April 2026.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | SGX |
| Ticker | SGX:P8A |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Listed and trading |
Get in touch
Contact
- Address
- Singapore
- Website
- sginvestors.io
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
On 23 April 2026, ahead of its 27 April 2026 AGM, Cordlife disclosed that its independent auditors had issued a disclaimer of opinion on the financial statements for the year ended 31 December 2025, citing unresolved regulatory and legal matters and an inability to verify opening balances as at 1 January 2025. This followed the Ministry of Health's one-year suspension of its licence to collect, test, process or store new cord blood units, effective 26 November 2025, and an MOH directive to replace the Chief Governance Officer and review laboratory records for roughly 160 cord blood units collected since January 2025. Source: Minichart AGM report, 23 April 2026.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
Every entity profile on variis is sourced. Not investment advice.